Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Do not recall ever seeing the data comparing the Sonis hamster model data with human drug trial data. Maybe this was out there all along, and if so, it never got my attn. Were there lots of other drugs whose hamster results did not correlate, and we are not given that info? We have no way to know. But that bit of info is very exciting for B-OM.
Also- seems they keep talking IBD- Inflammatory Bowel Disease and not just UC, as they have all along to be fair, but maybe it just strikes me more now. Maybe it is also because there may be real efficacy with B-UP(S) then other inflammatory conditions seem within reach. How to formulate an approach to Crohn's(whole gut) harder to figure.
Ten patients for K ovarian? Extreme focus on MOA? Good luck with that, not so easy to pin down.
All this talk about oral preparation, must be far along a development path.
Please please just prove that K will work for ovarian CA, in pts, not with murine model only. So much focus on an oral prep, with no proven benefit IV in a real trial with controls- seems so cart before the horse
Encouraging presentation, Bertolino at least well-spoken
see prev answer
I mean really work, not work in the lab or with mice, or with p21 levels
I mean with survival in real trials. Duh.
It is interesting, isn't it?
They have never even shown that the drug will work, but they want a pill rather than IV. Why not just prove IV is beneficial with the ovarian trial?
I suppose it means they believe K will work IV so it is worthwhile to develop a pill, but why not just go ahead and prove it already.
Wait on it, wait on it, talking to FDA about a protocol....sigh
Of course oral would be a big advantage- but, it will mean losing a very large amnt of time for them to get right dosing established to move forward with trials.
same old, same old: is repeating all old news an update?
I guess, if you have nothing new to say.
Just as we feared, nothing new.
So will our questions elicit any new info(I sent a bunch, as did others I see)?
I doubt it
So what other questions did people send in ?- remember that we have through today
questions for the 15th( for starters)
Dr bertolino, can you explain more about what is known of the science underlying the anti inflammatory actions of Brilacidin?
Dr Menon or Mr Ehrlich- did you ever try to alter the Kevetrin protocol to include more frequent dosing of such a short half life agent? Obviously, CTIX first needed to establish safety for kevetrin at higher doses. Having already done that, though, it would be very helpful to know if Kevetrin alone has any anticancer activity at more frequent dosing. The company has now lost many months of time when it might have been possible to determine this much earlier.
Dr Bertolino- you have said that the the hypersensitivity reaction with Prurisol does not occur, not a case, with Prurisol, so long as one excludes those genetically predisposed to the reaction. Is the data that clear cut?
Dr Ehrlich- can you provide an update on your lead gram negative candidate with respect to alteration to provide Pseudomonas coverage?
Let's get ready for...nothing whatsoever helpful or informative on 11/15. It will be stock answers, things we already all know, and likely a big waste of time. My prediction, anyway.
But I will still submit a few questions
the irony is that with incremental good news- B-UP promising, P2a results promising, P ready to go for next phase 2b, B-Om trail site expansion- the share price drops.
Rather than going up.
.89. Come to papa.
new resistant Candida species- C auris- causing deaths as you have likely read.
Wonder if ctix has any compounds that might help? They have of course mentioned antifungal activity in the past.
above or below 1? Where will ctix finish another dreary- no doubt -trading week? This is all we have to look forward to, sadly.
Maybe they can re-release the B-UP data in yet another PR of the same data, like last time?
Or maybe there will be one more patient to add to the mix?
Instead of just a 6 week update for P they need a 2 and a 4 and an 8 as well- final data now slides back to q3 it is announced!
oh yeah?
When exactly, should we anticipate this top blowing?
yeesh
We have a product that already had a successful phase 2, and where has it gotten us? B phase 2 for cellulitis had excellent results. A big partnership? It has gotten us nowhere
So why should P2 b be such a guaranteed partner magnet?
Arthur is gonna deal- really?
It is a good discussion topic .
But we already have a drug farther upstream than P that has brought no big deal
What could be more exciting? Yawn. Non news....
prob nothing bad....just nothing, for many months
(unless there is an update on B-OM 2 months from now....)
prepare for ctix hibernation! A bit more warm weather here in the Boston area- near 80 today and tomorrow, of all things. But after that, look for the stock to resurface next spring
Check back for B-OM and P 2b late spring early summer.
you predict otherwise then? On what grounds?
only if partner, which will not happen yet
don't hold your breath
no chance of rise in share price until May/June
Hey TIAB! You moron. Do you have zero understanding of biotech investing? Sell already. There are plenty of us here who understand that patience and suffering are virtues and we can maintain the watch very well without you.
I did predict that B-UP positive news would not move the stock up.
I would never have predicted that the share price would just keep sinking after good news though.
And yet, very reminiscent of P 2a results. Basically good news, followed by a fall
What a stock. One day we may see some benefit to ownership here, but it is not for many months now, at the very least.
did you just say the the lower the share price is the more room there is to move up?
The silver lining search...ah!
The going rate of money to get someone to be in a trial where multiple sigmoidoscopies are required? I haven't a clue.
But it might explain why the trial is not in the US
so much for moving the share price with positive B-UP news.
If about 1/4 is the rate of improvement without therapy, the numbers are very small, but are promising. It is encouraging news for shareholders. For the market, still too unknown to get a price rise? News released on a holiday? Patient numbers just too small? and no controls? Who knows, no share price impact, but a good start
so if the market will agree make a prediction for share price if stellar results UP interim data-
I still say 10% bump then settles back down
Pls disagree
There is a very big difference in a randomized trial(OM) versus unrandomized(UP) in terms of convincing potential partners of the worth of the B antiinflammatory potential.
Sure any benefit will be nice for UP
Broader applicability- success in several diseases- also impt
I still doubt any big share jump even with stellar UP results. Will be interesting to see
It is the ONLY chance of a move for 9 months
very nice graphics in article too, worthy of a peek
yes disappointing no mention of K
kudos to "pabanker" who mentions K in the comments
I will try to read more then- but to me it looked as though the timeline mentioned in prev post included fairly recent stuff, and I am not up to speed on old or new in this regard. I try to pay very close attn to the medicine part of ctix and the financial stuff goes by me for the most part
your reporting about this is valuable and eye opening
So maybe this is some of what got Farraye interested- ability to give orally with poor uptake plus PDE inhibition. Would be good for a UC or Crohn's drug- give orally but not well absorbed into bloodstream so limits exposure/side effects. But reaches the epithelium. As many of you may know lots of effort expended to develop steroids that would act on the intestinal epithelium but limit systemic exposure to steroids
(Obv also explains why Brilacidin for cellulitis given by IV- for absorption)
Interesting also the stuff you posted about crohn's and E coli and Serratia and Candida and biofilms in a small article that came out over the wknd. I came across it too. Brilacidin of course should get E Coli, unsure about Serratia(did poorly against Serratia in the ARVO paper about eye pathogens) maybe some Candida too- I don't know. Then it might have multiple modes of action in diseases where inflammation and bacteria re all part of the picture
Who knows how it will turn out- but it is interesting
If anyone found the first bit of P data that compelling, there would already be a partnership.Instead, the share price declined....and we will have to wait for P2b, and hope for the best.
anyone paying the least bit of attn to this stock knows that antiinflamm possib with B are big
However, report will be about first few B up pts only, no controls, as we all know
Later data with controls will be worth a great deal to share price and to partners- of course we agree on this
What data did they show to Farraye to get him as part of the team?
No way share price will react much to good news about UP interim results. Maybe short term 10% bump?
If you see it differently, we shall soon see
And I did think prior to each post.
At least I thought I thought.
I think therefore I post.
2b or not 2b?
originally results by end of 2nd Q promised for p2b.
now it is an interim analysis?
in other words no data to move stock until may june
as i said
it's a short trial. How much of an interim can be expected?
of course partnership would be big news.
But the reality is that there is NO big news any time soon, and nothing that will start the ctix rocket ship.
Next bit of news is B UP update, and that might move the price a bit , but we are waiting for P and waiting for B OM. Certainly no partner possible till post P2b
The day when CTIX could shoot meteor like to infinity and beyond is not at hand- yet.
Such critical info that we do not know about dropouts- of course not included in the 9/19 presentation or otherwise. I suppose we have to believe them when they say that more placebos dropped out.
Seriously, would Bertolino sign on if the data were not good? That gives me hope.
I get that the numbers are small.
Yes, sigh, the numbers are small for improvement for those with moderate disease at 200, and everything else is...nothin' doin'. Excellent post re Stellara dropout rate and other dropout rates- hard to believe only 7% in many trials woulda guessed higher.
Thnks for the posts- they are spot on.
Obv they can do a next study including psoriatic arthritis patients at a later time, and maybe that is the plan, since most pts with psoriasis do not have arthritis
How many studies validate IL-20 as a good biomarker for psoraitic arthritis?
What about all of the other -umabs that do not target IL-20, but are VERY effective against psoriasis/psoriatic arthritis?
Cannot easily compare Otzela/Prurisol, unless we know how much of Otzela sales are for pts with psoriatic arthritis.
As you recall, no sign that CTIX will test pts with arthritis vs skin disease only, while Otzela treats both
One patient
3 patients
4 patients
In a trial where many other patients are included. No?
Nonetheless, you are right, and I am wrong.
New science, however preliminary is still new. Maybe we can all go back and read the exciting first patient interim update again, as we anticipate new data on 2 more people. Or even 3 more.